Medical News

RSS

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

Genmab A/S announced today the start of a Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.

26 Oct 2010

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Klaus Ley, M.D, a scientist at the La Jolla Institute for Allergy & Immunology, was recently awarded the prestigious Malpighi Medal at the World Congress for Microcirculation in Paris, France. A lifetime achievement award presented by the European Society for Microcirculation, Dr. Ley received the honor in recognition of his pioneering endeavors in vascular immunology, a scientific discipline that he helped to pioneer, which looks at novel immune-based approaches to combating heart disease. He is only the 17th recipient of the biennial award worldwide.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

Pre-retirees concerned over rising healthcare costs

Nearly two-thirds (62 percent) of pre-retirees ages 50-64 are not at all confident that they are saving enough to handle healthcare costs in retirement, according to a new survey from the Society of Actuaries (SOA). Additionally, only seven percent of participants said they are very confident about having enough savings.

26 Oct 2010

Savient to evaluate strategic alternatives for KRYSTEXXA drug

Savient Pharmaceuticals, Inc. announced that its previously announced process to identify, following the approval of KRYSTEXXA by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.

26 Oct 2010

AAHP highlights safety of homeopathic children's medicines

The American Association of Homeopathic Pharmacists (AAHP), representing the major manufacturers and distributors of homeopathic drugs, highlights the safety of homeopathic children's medicines in response to the recall of Hyland's Teething Tablets. The AAHP supports the efforts to protect the safety of children by both the Standard Homeopathic Company and the U.S. Food and Drug Administration (FDA).

26 Oct 2010

Physiotherapy Associates announces affiliation with National Multiple Sclerosis Society

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, today announced that it has identified the National Multiple Sclerosis Society as its national community service partner. More than 3,100 employees for Physiotherapy Associates will provide ongoing community service efforts to benefit the more than 400,000 people living in the United States with multiple sclerosis (MS).

26 Oct 2010

Examining genetic material of egg cells may inform about embryos health

Fertility procedures such as in vitro fertilization (IVF) require a couple and the doctor to place the risky bet that the multiple eggs they choose to fertilize will produce an embryo that will thrive in the uterus. Researchers cannot biopsy eggs directly because that would destroy them, but a new discovery by professors at Brown University and Women & Infants Hospital could lead to new insights about how eggs develop and ultimately inform judgments about how the embryos they produce will fare. The idea is to examine the genetic material the egg cells discarded when they were first forming, to see which genes they were expressing.

26 Oct 2010

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).

26 Oct 2010

Trius receives patent protection for torezolid phosphate in the U.S.

Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).

26 Oct 2010

Panel examines global food security ahead of LA Francophonie summit; Global Fund, UNAIDS call for greater cooperation among French-speaking countries

World Trade Organization Director-General Pascal Lamy highlighted concerns about the global food situation on Friday during a roundtable discussion on the sidelines of the International Organisation of La Francophonie summit, Agence France-Presse reports.

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

The John Theurer Cancer Center at Hackensack University Medical Center unveiled a new $130-million, 155,000-square-foot comprehensive cancer facility that will enhance the cancer center's ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. The doors will open for patients in January 2011.

26 Oct 2010

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Cholera epidemic in Haiti persists despite slow down in fatalities

"A multinational medical response has slowed deaths in a Haitian cholera epidemic that has killed more than 250 people so far, but the outbreak is likely to widen, a senior U.N. official said on Sunday," Reuters reports. The U.N., Haitian government and aid partners "have launched a major effort to try to contain the epidemic" of more than 3,000 cases in the country so far (Delva, 10/25). The New York Times reports that the death rate, according to the Haitian government, has "declined - from 10.6 percent of known cases three days earlier to 8.2 percent now."

26 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

New York Times profiles USAID Administrator Shah

The New York Times profiles USAID Administrator Rajiv Shah and examines the challenges that come with leading the development agency at this point in time.

26 Oct 2010

SNP array's snapshot of Anopheles gambiae genome can help eliminate malaria

The development and first use of a high-density SNP array for the malaria vector mosquito have established 400,000 genetic markers capable of revealing new insights into how the insect adapts to outsmart insecticides and other preventive measures, according to findings published in the current edition of the journal Science.

26 Oct 2010

Chemoradiotherapy can reduce bladder cancer recurrence

A major bladder cancer trial, funded by Cancer Research UK, has shown that adding two commonly used chemotherapy drugs to traditional radiotherapy can reduce the chance of a patient's tumour coming back by a third.

26 Oct 2010

Smokers with anxiety disorders less likely to quit smoking

Researchers may have pinpointed a reason many smokers struggle to quit. According to new research published in the journal Addiction, smokers with a history of anxiety disorders are less likely to quit smoking. The study, conducted by the University of Wisconsin Center for Tobacco Research and Intervention (UW-CTRI), offered free coaching and medications to smokers in Madison and Milwaukee.

26 Oct 2010

Medical News

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

La Jolla Institute scientist wins Malpighi Medal for pioneering work in heart disease

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Pre-retirees concerned over rising healthcare costs

Savient to evaluate strategic alternatives for KRYSTEXXA drug

AAHP highlights safety of homeopathic children's medicines

Physiotherapy Associates announces affiliation with National Multiple Sclerosis Society

Examining genetic material of egg cells may inform about embryos health

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Trius receives patent protection for torezolid phosphate in the U.S.

Panel examines global food security ahead of LA Francophonie summit; Global Fund, UNAIDS call for greater cooperation among French-speaking countries

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Cholera epidemic in Haiti persists despite slow down in fatalities

Salk discovers potential new target for MS

New York Times profiles USAID Administrator Shah

SNP array's snapshot of Anopheles gambiae genome can help eliminate malaria

Chemoradiotherapy can reduce bladder cancer recurrence

Smokers with anxiety disorders less likely to quit smoking

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News